FY2024 EPS Estimates for YS Biopharma Co., Ltd. (NASDAQ:YS) Lowered by Analyst

YS Biopharma Co., Ltd. (NASDAQ:YS) – Analysts at Diamond Equity dropped their FY2024 EPS estimates for YS Biopharma in a research report issued to clients and investors on Monday, April 22nd. Diamond Equity analyst H. Diamond now forecasts that the company will post earnings per share of ($0.45) for the year, down from their prior estimate of ($0.24). The consensus estimate for YS Biopharma’s current full-year earnings is ($0.24) per share. Diamond Equity also issued estimates for YS Biopharma’s Q4 2024 earnings at ($0.08) EPS, Q1 2025 earnings at ($0.09) EPS, Q2 2025 earnings at ($0.08) EPS, Q3 2025 earnings at ($0.06) EPS, Q4 2025 earnings at ($0.02) EPS and FY2025 earnings at ($0.25) EPS.

YS Biopharma Price Performance

Shares of NASDAQ YS opened at $0.81 on Thursday. The company’s fifty day moving average is $0.65 and its 200-day moving average is $0.57. YS Biopharma has a twelve month low of $0.35 and a twelve month high of $1.97. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.09.

YS Biopharma (NASDAQ:YS) last announced its quarterly earnings results on Monday, January 22nd. The company reported ($0.16) earnings per share for the quarter. The firm had revenue of $13.64 million for the quarter.

Hedge Funds Weigh In On YS Biopharma

A hedge fund recently bought a new stake in YS Biopharma stock. Superstring Capital Management LP acquired a new stake in YS Biopharma Co., Ltd. (NASDAQ:YS) during the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 307,920 shares of the company’s stock, valued at approximately $166,000. Superstring Capital Management LP owned approximately 0.33% of YS Biopharma at the end of the most recent quarter. 52.64% of the stock is currently owned by hedge funds and other institutional investors.

About YS Biopharma

YS Biopharma Co, Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001.